Trial
NCT07111013
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Bausch & Lomb Incorporated
Collaborators
—
Condition
Dry Eye Disease
Intervention
Lifitegrast/perfluorohexyloctane (PFHO)
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-10